Leishmaniases control: what part for development and what part for research?  by Bastien, P.
Leishmaniases control: what part for development and what part
for research?
P. Bastien1,2
1) Universite´ Montpellier 1 (UFR Me´decine) and Centre Hospitalier Universitaire, Laboratoire de Parasitologie-Mycologie, National Reference Centre (CNR)
for Leishmania and 2) UMR MIVEGEC (IRD 224-CNRS 5290-Universite´ Montpellier 1), Montpellier, France
E-mail: p-bastien@chu-montpellier.fr
Article published online: 31 May 2011
Leishmaniases are a complex group of parasitic diseases, nor-
mally transmitted through the bite of an infected (phleboto-
mine) sandﬂy, and caused by 20 or so human-pathogenic
species of the obligate intracellular protozoon Leishmania (of
the Trypanosomatid family). They are endemic in 98 coun-
tries on the four main continents and still constitute a major
public health problem, causing relatively low mortality but
considerable morbidity. As noted by den Boer et al. in this
issue [1], their impact is essentially associated with poverty.
Prevalence has long been estimated as about 12 million cases
worldwide, with 2 million new cases occurring every year.
According to disease-burden estimates, leishmaniases rank
second in mortality and fourth in morbidity caused by
neglected tropical diseases [2]. The epidemiology of these
diseases is complex, based on anthropo-zoonotic cycles
involving a large diversity of sandﬂy vectors and mammalian
reservoirs depending on the Leishmania species [3]. In many
epidemiological settings, human is an accidental host, except
for L. donovani in the Indian subcontinent and L. tropica in the
Near and Middle East, for which humans are sufﬁciently
infected to constitute a reservoir. Yet, in spite of an increas-
ingly good knowledge of their epidemiology, leishmaniases
essentially remain uncontrolled diseases. The struggle against
poverty is probably the ﬁrst line to their control, but, in any
case, we do not have that many weapons to combat them.
In this Theme Issue, various difﬁcult aspects of the ﬁght
against these diseases are reviewed: pleiomorphism of the
clinical presentation, role of the relatively recently discov-
ered asymptomatic carriers, access to therapy, drug treat-
ment and vaccine.
Leishmaniases produce a wide spectrum of clinical symp-
toms, ranging from self-healing cutaneous lesions to severe
visceral disease or mutilating mucosal involvement. These dif-
ferent clinical categories are essentially related to the Leish-
mania species involved, showing visceral or cutaneous
tropism, or again a capacity for metastases to facial mucosa.
Yet, more than 7 years after the completion of the ﬁrst
Leishmania genome sequence [4], it is unclear why certain
species give different clinical signs. Worse, this typical
scheme may sometimes be reverted (e.g. cutaneotropic spe-
cies causing visceral disease); and an extreme clinical pleio-
morphism is observed in cutaneous leishmaniasis. Such a
variety of presentations may be the result of both host and
parasite factors, which are difﬁcult to disentangle; this is fur-
ther complicated by the inﬂuence of the bite of the insect
vector, which has become the subject of many studies. This
complex intertwining of factors affecting the variable out-
come of infection is examined by Ban˜uls et al. in this issue
[5]. Asymptomatic carriage (also termed ‘subclinical’ or
‘cryptic’ leishmaniasis) is an extreme form of this polymor-
phism, as it has clearly appeared since 2000 that patent dis-
ease is probably only ‘the emerged tip of the iceberg’. The
critical question of the role of asymptomatic carriers in the
epidemiology of leishmaniases is here addressed by Ban˜uls
et al. [5], and their potential impact upon elimination cam-
paigns of the disease is pertinently highlighted by Kaye and
Aebischer [6].
The issue of the translation of basic research into con-
crete actions for control is acutely posed through the follow-
ing review articles. The case of drug therapy is a particularly
good example of this contradiction. Certainly, the main
problem today in endemic areas is not so much having efﬁ-
cient drugs as getting them to the patient and making them
affordable; den Boer et al. [1] address this question here and
show how the WHO endeavours to coordinate all the
actors involved for improved drug access. In a timely review,
they highlight the numerous and ill-known factors that actu-
ally impede access of the infected populations to treatment.
Drug supply is one of these, but all depends not only on the
national infrastructures, but also on ensuring continuous and
stable production, verifying drug quality according to good
manufacturing practice standards, establishing national treat-
ment protocols and effective forecast systems, and effective
registration of the drug in the country.
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Be that as it may, the treatment of leishmaniases still relies
upon a limited number of drugs that are essentially toxic,
expensive and relatively inefﬁcient. In spite of decades of
progress, we are indeed far from having safe, cheap, easily
administered and efﬁcient anti-leishmanial drugs. After den
Boer et al. [1], Croft and Olliaro, in this issue [7], review the
drug treatments and combination therapies currently in use
for both cutaneous and visceral leishmaniases, underline the
need for randomized placebo-controlled trials and improved
clinical pharmacokinetic information, and highlight the even-
tual challenges and opportunities for drug research and
development.
The search for a vaccine is obviously another avenue in
the ﬁght against leishmaniases; but, as for other eukaryotic
microorganisms, it is extremely challenging. As the highly
complex immune response to Leishmania infection is exten-
sively reviewed elsewhere, Kaye and Aebischer, in this issue
[6], focus part of their review upon the lack of knowledge
that hampers the understanding of the immune protection
following vaccination (e.g. relationships between vaccine-
induced antibody responses, or infectious dose, and
subsequently acquired immunity). Interestingly, they stress
that a better understanding of the life cycle of Leishmania in
its mammalian host would help to resolve a number of ques-
tions related to vaccine success. They then tell us about
recent progress and future prospects of vaccine development
for visceral leishmaniasis, the most severe form of these dis-
eases. In view of the lack of clinical efﬁcacy of ﬁrst-genera-
tion vaccines, they support the use of therapeutic vaccine
trials as an effective adjunct to chemotherapy and a ﬁrst step
to protective vaccine development. Hence, their original
review highlights the complexity of factors intertwined in the
elaboration of an efﬁcient vaccine for leishmaniases.
Controlling neglected tropical diseases must obviously rely
upon developing the standard of living, encouraging political
responsibility and improving national health systems [1]. On
our side, we search for weapons to efﬁciently ﬁght against
the parasite. Modern research should, in time, succeed in
providing new tools for controlling leishmaniases: for exam-
ple, the now classical ‘-omics’ ﬁeld (transcriptomics, proteo-
mics, including ‘phosphoproteomics’ and ‘kinomics’,
metabolomics, interactome) will continue helping to reﬁne
our views about gene expression (as an example, see [8]);
similarly, with genomics, the continuously expanding ﬁeld of
high-throughput sequencing will provide more ‘individual’
(strain) genome sequences (for example, see the National
Human Genome Research Institute proposal at: http://
www.genome.gov/Pages/Research/DER/PathogensandVectors/
PathogensofTrypanosomatid.pdf). The progress in micros-
copy and cell biology will help to unravel the role of the 60%
of proteins of unknown function in this genome. In my view,
one of the keys for future discovery of novel control tools is
the elucidation of highly speciﬁc metabolic pathways, molecu-
lar cascades and biological mechanisms that are essential to
the parasite but absent in humans, leading for example to
the identiﬁcation of potential drug targets. The collection of
new data should allow understanding of speciﬁc differences
between developmental stages, Leishmania species and even
strains, with respect to tissue tropism, immunogenicity, viru-
lence and drug sensitivity [9]. There are, and there will be,
other technological developments that will open more ave-
nues to entering the heart of the ‘beast’. In parallel, the
struggle against poverty should never cease. The battle is dif-
ﬁcult but not lost.
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